Trending...
- Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership
- Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
- Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
Extension of Series A Supports Operations Expansion and Increased Promotion
PHILADELPHIA - PennZone -- ExpressCells, Inc., a private genetic engineering company that creates knock-in cell lines to support biological research, today announced that it has completed an extension of its Series A financing round. The company raised $590,500 in this Series A2 round from both existing and new investors. This round was oversubscribed by 18%.
New investors in ExpressCells include the MIT Alumni Angels of Northern California, the Orange County Chapter of Tech Coast Angels, and the Berkeley Angel Network. Existing investors who also invested in this round include the Rowan Innovation Venture Fund, the Central Texas Angel Network, Robin Hood Ventures, and Ben Franklin Technology Partners of Southeastern Pennsylvania.
ExpressCells is using the $590,500 raised in this round to expand its operational infrastructure to support the increasing demand for its knock-in cell lines. The company also will increase promotion to the biological research community.
More on The PennZone
"This funding allows ExpressCells to meet the rapidly-growing demand from both industry and academic customers. We are thankful to the new investors who have joined our Series A," said Matt Handel, co-founder and CEO of ExpressCells. "We also appreciate the additional funding from our existing investors."
Interest in this round of financing was driven, in part, by recent news events for ExpressCells. Pepperdine Graziadio Business School named ExpressCells to its 2020 Most Fundable Companies® List and ExpressCells was one of top three startups—and the top life sciences company—in the Pismo Venture's National Venture Plan Competition.
About ExpressCells
ExpressCells uses its proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other types of biological research. The speed of the process allows ExpressCells to insert one to three genes into the same cell line months faster than other technologies. The company currently has 17 customers and expects that number to grow.
ExpressCells sells both custom and catalog cell lines. For more information, visit xpresscells.com (http://www.xpresscells.com/).
New investors in ExpressCells include the MIT Alumni Angels of Northern California, the Orange County Chapter of Tech Coast Angels, and the Berkeley Angel Network. Existing investors who also invested in this round include the Rowan Innovation Venture Fund, the Central Texas Angel Network, Robin Hood Ventures, and Ben Franklin Technology Partners of Southeastern Pennsylvania.
ExpressCells is using the $590,500 raised in this round to expand its operational infrastructure to support the increasing demand for its knock-in cell lines. The company also will increase promotion to the biological research community.
More on The PennZone
- NEW SEASON OF "The Really Real Estate" APPROVED
- UK Financial Ltd Announces Full Ecosystem To Erc-3643 "SEC-Ready" Tokens For All UK Financial Ltd Tokenized Projects
- Pushing the Wave Series Launches Premium Hardback Editions of 2017–2022 and 2023 Volumes
- ZEELOOL 2025 Black Friday and Cyber Monday Big Deals
- Americans Are Building Family Legacies That Last Generations — Not Just Paychecks That Last a Month
"This funding allows ExpressCells to meet the rapidly-growing demand from both industry and academic customers. We are thankful to the new investors who have joined our Series A," said Matt Handel, co-founder and CEO of ExpressCells. "We also appreciate the additional funding from our existing investors."
Interest in this round of financing was driven, in part, by recent news events for ExpressCells. Pepperdine Graziadio Business School named ExpressCells to its 2020 Most Fundable Companies® List and ExpressCells was one of top three startups—and the top life sciences company—in the Pismo Venture's National Venture Plan Competition.
About ExpressCells
ExpressCells uses its proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other types of biological research. The speed of the process allows ExpressCells to insert one to three genes into the same cell line months faster than other technologies. The company currently has 17 customers and expects that number to grow.
ExpressCells sells both custom and catalog cell lines. For more information, visit xpresscells.com (http://www.xpresscells.com/).
Source: ExpressCells, Inc.
0 Comments
Latest on The PennZone
- The 7 Visibility Problems Costing Independent Hotels Thousands Every Month
- Viola's Babygirl's, LLC Proudly Announces Teri Tobin's Soulful New Christmas EP "Home For The Holidays"
- Stoxtel Introduces High-Throughput "Matrix" Engine to Address Mexico's Crypto Trading Volatility
- Eagles LB Jihaad Campbell Brings Surprise Visit for Together We Dance Foundation
- UK Financial Ltd Sets Listing Date With Catex Exchange For The Listing Of Mayacat The World's First Ever Gold Backed ERC 3643 "SEC Ready" Token
- Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
- Althea Gibson Honored as Final Release in U.S. Mint's American Women Quarters Program
- ToneWell Launches AI Wellness Platform with 30-Second Voice-Based Performance Readiness Scan™
- Lokal Media House Achieves Yelp Platinum Partner Status
- World's First AI-Native Industrial Facility is Under Construction by Carbon AMS with rhobot.ai
- VIP Vacations Wins Diamon Status with AIC Hotel Group
- $57 Billion U.S. Marine Industry Presents Major Growth Opportunity for Newly Public Off The Hook Yacht Sales, Inc. (N Y S E: OTH)
- Deimler Chiropractic Announces Expansion
- Dr. Alexander Eastman Returns to Suburban Hospital to Deliver Keynote on Crisis Leadership
- Scoop Social Co.'s Mobile Dessert Truck Business Offer A Lifestyle Of Flavor, Fun, and Freedom
- Own 327 Acres of American Prime Real Estate with 2 Miles Waterfront Worth In Millions for Just $7 — Worldwide Raffle Launched
- Lakefront Acreage in Longwood's Ravensbrook Community Hits the Market
- Monika Balayan Elected Fellow of the Royal Society of Arts (FRSA)
- Best Companies Group Launches Best Companies to Work for in New York Program
- We're Winning: Historic Plunge in Overdose Deaths Marks Stunning Reversal in America's Drug Crisis